MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Key interaction in cholesterol regulation

Back to heart watch blog Blogs list Cancer blog  


Subscribe To Heart Watch Blog RSS Feed  RSS content feed What is RSS feed?

Key interaction in cholesterol regulation




Scientists at UT Southwestern Medical Center have determined the specific way in which a destructive protein binds to and interferes with a molecule that removes low-density lipoproteins (LDL), the so-called bad cholesterol, from the blood.

The practical benefit of this finding is that we can now search for new ways to lower cholesterol by designing targeted antibodies to disrupt this interaction, said Dr. Jay Horton, professor of internal medicine and molecular genetics and a senior author of the study, which appears online this week in the Proceedings of the National Academy of Sciences.
The protein, called PCSK9, has emerged as an important regulator of bad cholesterol in the blood, said Dr. Horton, whose research focuses in part on understanding the proteins function.



Key interaction in cholesterol regulation

PCSK9 disrupts the activity of a key molecule called the low-density lipoprotein receptor, or LDLR. This molecule, which juts out from the surface of cells, latches on to bad cholesterol in the bloodstream and removes it by drawing it into the cells.

The PCSK9 protein also can latch on to the LDL receptor. This binding, however, triggers a chain of biochemical reactions that leads to the destruction of the LDL receptor. With fewer receptors available, more bad cholesterol remains in the bloodstream.

You want to have LDL receptors to clear LDL from the blood thats a good thing, Dr. Horton said. So you dont want to have PCSK9; it normally functions in a harmful way.

Too much LDL cholesterol in the blood is a major risk factor for heart disease, heart attack and stroke because it contributes to the buildup of plaque that clogs the walls of arteries. More than 25 million people worldwide take a class of drugs called statins to lower their cholesterol to within recommended healthy levels.

To determine exactly how PCSK9 and the LDLR physically interact, the researchers, led by Dr. Hyock Joo Kwon, an instructor in biochemistry, collaborated with Dr. Johann Deisenhofer, professor of biochemistry, an investigator with the Howard Hughes Medical Institute and a senior author of the study. Dr. Deisenhofer shared the 1988 Nobel Prize in Chemistry for his work in discovering the structure of a key protein involved in photosynthesis.

Using X-rays bounced off crystals made up of both PCSK9 and a portion of the LDLR protein, the scientists identified small regions of each protein that attach to each other. They then created a detailed structural model of the area.

It looks like those portions are absolutely essential for the interaction to take place, Dr. Horton said.

The scientists are now designing antibodies and small chains of peptides the building blocks of proteins that have the ability to jam the interaction between LDLR and PCSK9.

Dr. Hortons prior studies have shown that mice lacking PCSK9 have LDL cholesterol levels less than half that of normal mice.

Studies by other UT Southwestern scientists have observed that people with mutations in the PCSK9 gene, which prevented them from making normal levels of the PCSK9 protein, had LDL cholesterol levels 28 percent lower than individuals without the mutation and were protected from developing coronary heart disease. That research was led by Dr. Jonathan Cohen, professor of internal medicine, and Dr. Helen Hobbs, director of the Eugene McDermott Center for Human Growth and Development.

While statin drugs work by increasing the number of LDL receptors on cells, a drug targeting PCSK9 might prevent the existing receptors from being degraded.

These studies suggest that inhibiting PCSK9s action may be another route to lowering LDL cholesterol in individuals with high cholesterol, said Dr. Horton.


Posted by: Daniel    Source




Did you know?
Scientists at UT Southwestern Medical Center have determined the specific way in which a destructive protein binds to and interferes with a molecule that removes low-density lipoproteins (LDL), the so-called bad cholesterol, from the blood. The practical benefit of this finding is that we can now search for new ways to lower cholesterol by designing targeted antibodies to disrupt this interaction, said Dr. Jay Horton, professor of internal medicine and molecular genetics and a senior author of the study, which appears online this week in the Proceedings of the National Academy of Sciences.

Medicineworld.org: Key interaction in cholesterol regulation

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.